People often ask about MOTS-c and metformin because both come up around cellular energy. As of October 17, 2026, the day this article was written, PubMed and ClinicalTrials.gov searches identified no published human trial administering both together. Their combined effects, interaction rates, and safe schedules remain unknown.
That gap reflects what published studies have tested so far, not proof that nobody has used both. A missing trial is neither permission to combine them nor proof of a medical contraindication.
Both names usually meet around an enzyme called AMPK, which acts like a cell's fuel gauge. Sharing a pathway in lab studies does not mean two compounds work alike in people. It does not show that they double each other's effects or replace one another.
Why MOTS-c and metformin come up together
MOTS-c is a chain of 16 amino acids, the building blocks of protein. Its genetic code sits inside mitochondria, the cell structures that turn food into energy. In a 2015 study in Cell Metabolism, Changhan Lee and colleagues tested MOTS-c in cells and mice.
In those lab experiments, MOTS-c shifted cellular folate processing and raised AICAR, a natural trigger for AMPK. In mice on a high-fat diet, it promoted AMPK activation and increased levels of GLUT4, a protein that helps move sugar into muscle cells. Detecting natural MOTS-c in human blood is not the same as giving the peptide as a medicine.
Metformin is an oral biguanide drug labeled in the United States for type 2 diabetes. In the August 2026 U.S. prescribing information on DailyMed (Revised: 8/2026), the mechanism section lists three main actions. It lowers liver glucose output, cuts gut glucose absorption, and helps tissues use sugar without raising insulin secretion.
Section 12.1 of the metformin label does not mention AMPK. Instead, AMPK appears in research reviews—such as a 2016 Cell Metabolism paper by Nir Barzilai and colleagues—as one proposed mechanism.
| Feature | MOTS-c | Metformin |
|---|---|---|
| Type | 16-amino-acid mitochondrial peptide | Oral biguanide medication |
| U.S. status | Different from an FDA-approved drug; not FDA-approved | Prescription drug labeled for type 2 diabetes |
| Mechanism | Cell and mouse studies report AMPK activation | Label cites lower liver glucose output, gut absorption, and better uptake |
| Co-treatment trials | None identified in October 17, 2026 searches | None identified with administered MOTS-c |
What human research on the pair actually tested
A published human biomarker study connects the two names, and nobody in it received MOTS-c treatment. Elisabet Cuyàs and colleagues published that exploratory study in Aging (Albany NY) online in December 2022 and in print in February 2023.
They tested stored blood from 38 women with HER2-positive breast cancer in the METTEN trial, with 19 per group. Both groups received 24 weeks of chemotherapy and trastuzumab, and one group also took metformin. Researchers used a laboratory blood test to measure the body's own MOTS-c before and after treatment.
The groups showed no statistically significant difference in natural MOTS-c changes. Limits included a small cancer sample, blood draws not timed to metformin doses, and differences across MOTS-c lab tests. Measuring natural hormone levels does not test taking MOTS-c alongside metformin.
On ClinicalTrials.gov, Hudson Biotech registered a separate Phase 2a study called MOTS-MET, updated April 1, 2026. It lists an estimated 120 adults aged 18 to 65 with prediabetes and overweight or obesity. The registered plan assigns participants equally to MOTS-c or placebo with lifestyle counseling for 12 weeks.
Primary outcomes track insulin sensitivity from an oral glucose test at week 12 and side effects through week 16. No results are posted, and it excludes metformin, GLP-1 drugs, or SGLT2 inhibitors within three months before screening. That three-month rule is a study eligibility criterion, not advice to stop prescribed metformin.
What a doctor weighs if you already take metformin
When someone on metformin asks about a peptide, a clinician starts with why metformin was prescribed. Its U.S. label covers type 2 diabetes, and guidelines also discuss two common metabolic uses.
The 2026 American Diabetes Association Standards of Care say metformin should be considered to prevent type 2 diabetes in high-risk adults. The 2023 international guideline hosted by the American Society for Reproductive Medicine uses polyendocrine metabolic ovarian syndrome (PMOS) for the condition formerly called PCOS.
It says metformin alone should be considered for metabolic outcomes in adults with PMOS and a BMI of at least 25. Below 25, it may be considered, acknowledging limited evidence. Neither guideline recommends adding MOTS-c, and peptides for insulin resistance covers broader metabolic options.
Metformin's August 2026 U.S. label carries a boxed warning for lactic acidosis, a rare and potentially fatal acid buildup in the blood. Symptoms include malaise, muscle pain, abdominal discomfort, breathing trouble, and unusual sleepiness. Suspected metformin-associated lactic acidosis calls for immediate discontinuation and hospital supportive care; prompt hemodialysis is recommended.
The label contraindicates metformin when a kidney-filtering score (eGFR) is below 30. Starting metformin is not recommended at an eGFR of 30 to 45.
Metformin use is also not recommended in inherited mitochondrial diseases such as MELAS or MIDD. Those rare genetic conditions are a metformin label warning, not evidence of a MOTS-c interaction.
Clinicians also pause metformin before or during certain iodinated contrast imaging procedures. This applies at an eGFR of 30 to 60, with a history of liver disease, alcoholism or heart failure, or with intra-arterial iodinated contrast. The label calls for kidney reassessment 48 hours afterward and restarting only if kidney function is stable.
The label calls for yearly blood counts and B12 checks every two to three years. ADA recommends periodic B12 assessment, with annual checks after more than four years of metformin or with other deficiency risks.
The label's patient information says metformin rarely causes hypoglycemia (low blood sugar) alone, though inadequate food or alcohol can contribute. Pairing it with insulin or sulfonylureas raises hypoglycemia risk and may require doctor-directed dose changes.
Effects with MOTS-c are unmeasured; see MOTS-c side effects for standalone safety. Routine changes are prescriber-directed; suspected lactic acidosis requires immediate discontinuation and hospital care.
Metformin for longevity vs MOTS-c
People also compare metformin and MOTS-c in discussions about aging. In their 2016 Cell Metabolism paper, Barzilai and colleagues proposed the Targeting Aging with Metformin (TAME) study. They planned to enroll 3,000 adults aged 65 to 79 across roughly 14 U.S. centers to track age-related chronic diseases and death.
That 2016 paper described a planned study design, not completed trial results. ClinicalTrials.gov searches on October 17, 2026 for the TAME aging trial did not identify that proposed study. Instead, searches returned unrelated studies, such as a polycystic kidney disease trial and a calorie-restriction follow-up.
Neither animal lifespan studies nor observational data prove that metformin or MOTS-c extends human life. Neither compound is approved as an anti-aging treatment.
FDA status, compounding, and anti-doping rules
Compounded MOTS-c is different from an FDA-approved medication: MOTS-c and the compounded formulation offered through Promise are not FDA-approved. In a May 11, 2026 FDA staff evaluation, reviewers assessed MOTS-c free base and MOTS-c acetate for the 503A bulk substances list. Staff found no identified human exposure data, wrote that human safety risks are unknown, and noted impurity, aggregation, and immune concerns.
The memo recommended against adding either form to the 503A list before the July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Advisory recommendations are non-binding, and our MOTS-c FDA review covers that record.
Even though MOTS-c has no FDA approval, a licensed provider may still prescribe — that decision is between you and your doctor. At Promise, a licensed provider reviews every request and not everyone qualifies. MOTS-c prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy.
Tested athletes face separate rules. Under the World Anti-Doping Agency's 2026 Prohibited List, in force today, MOTS-c is prohibited at all times in category S4.4.1 as an AMPK activator.
As of October 17, 2026, the day this article was written, WADA's September 21, 2026 release sets the next list for January 1, 2027. The 2027 Prohibited List keeps MOTS-c prohibited at all times in S4.4.1, while metformin is not named in either list. Because an unlisted name is not personal clearance, athletes should check their anti-doping authority and our WADA 2027 Prohibited List guide.
